William Blair upgraded shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) from a market perform rating to an outperform rating in a report issued on Monday morning, MarketBeat reports. William Blair also issued estimates for Arrowhead Pharmaceuticals’ Q1 2018 earnings at ($0.11) EPS, Q2 2018 earnings at ($0.19) EPS, Q3 2018 earnings at ($0.19) EPS and Q4 2018 earnings at ($0.19) EPS.

Several other equities research analysts also recently weighed in on the stock. Chardan Capital reaffirmed a neutral rating on shares of Arrowhead Pharmaceuticals in a report on Wednesday, September 13th. Cantor Fitzgerald reaffirmed a hold rating and issued a $2.00 price objective (up previously from $1.00) on shares of Arrowhead Pharmaceuticals in a report on Friday, September 15th. ValuEngine downgraded shares of Arrowhead Pharmaceuticals from a sell rating to a strong sell rating in a report on Friday, September 1st. Jefferies Group LLC reaffirmed a hold rating and issued a $2.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Friday, August 4th. Finally, Piper Jaffray Companies reaffirmed a hold rating and issued a $2.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Friday, July 28th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and one has issued a buy rating to the company’s stock. The company presently has an average rating of Hold and a consensus price target of $2.00.

Arrowhead Pharmaceuticals (NASDAQ ARWR) opened at 3.51 on Monday. The stock’s market cap is $262.45 million. The stock has a 50 day moving average of $2.49 and a 200-day moving average of $1.89. Arrowhead Pharmaceuticals has a one year low of $1.20 and a one year high of $8.09.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.06. The business had revenue of $9.34 million during the quarter, compared to the consensus estimate of $5.29 million. Arrowhead Pharmaceuticals had a negative net margin of 201.84% and a negative return on equity of 46.73%. Analysts anticipate that Arrowhead Pharmaceuticals will post ($0.42) EPS for the current year.

ILLEGAL ACTIVITY WARNING: This news story was reported by Daily Political and is the sole property of of Daily Political. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of international trademark and copyright laws. The legal version of this news story can be read at https://www.dailypolitical.com/2017/09/22/arrowhead-pharmaceuticals-inc-arwr-upgraded-to-outperform-by-william-blair.html.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Virtu KCG Holdings LLC lifted its holdings in Arrowhead Pharmaceuticals by 115.6% in the 2nd quarter. Virtu KCG Holdings LLC now owns 99,267 shares of the biotechnology company’s stock valued at $161,000 after acquiring an additional 53,215 shares during the last quarter. LMR Partners LLP acquired a new stake in Arrowhead Pharmaceuticals in the 2nd quarter valued at about $467,000. Geode Capital Management LLC lifted its holdings in Arrowhead Pharmaceuticals by 3.4% in the 1st quarter. Geode Capital Management LLC now owns 663,062 shares of the biotechnology company’s stock valued at $1,226,000 after acquiring an additional 21,654 shares during the last quarter. SG Americas Securities LLC lifted its holdings in Arrowhead Pharmaceuticals by 287.9% in the 1st quarter. SG Americas Securities LLC now owns 100,747 shares of the biotechnology company’s stock valued at $186,000 after acquiring an additional 74,776 shares during the last quarter. Finally, UBS Asset Management Americas Inc. lifted its holdings in Arrowhead Pharmaceuticals by 414.7% in the 1st quarter. UBS Asset Management Americas Inc. now owns 66,400 shares of the biotechnology company’s stock valued at $123,000 after acquiring an additional 53,500 shares during the last quarter. 20.61% of the stock is owned by institutional investors.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes.

Analyst Recommendations for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Receive News & Ratings for Arrowhead Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.